Trial NCT04383574
Publication Li M, medRxiv, 2021
Primary outcome on the report: Geometric mean titre (GMT) and seropositivity rate of neutralizing antibodies to live SARS-CoV-2 on day 180 after two-dose primary vaccination, and on days 7, 14, and 28 after the third dose. Any vaccine-related adverse event (adverse reaction) within 28 days after administration of the third dose of vaccine or placebo in phase 2 trial, and serious adverse events from immunization till 6 Healthy adults aged ≥60 years with no known history of COVID-19 or recent exposure in a single center in China months after two doses in both phase 1&2 trials.

Note: The risk of bias by domain corresponds to the highest risk of bias among outcomes by domain.
The overall risk of bias corresponds to the overall highest risk of bias assessed among outcomes.